Related references
Note: Only part of the references are listed.Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis
Xiaoxiang Zhou et al.
BMC MEDICINE (2020)
Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors
Lihong Peng et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Low-Density Neutrophils in Systemic Lupus Erythematosus
Sen Hee Tay et al.
ARTHRITIS & RHEUMATOLOGY (2020)
A decade of immune-checkpoint inhibitors in cancer therapy
Caroline Robert
NATURE COMMUNICATIONS (2020)
Activity of Nivolumab and Utility of Neutrophil-to-Lymphocyte Ratio as a Predictive Biomarker for Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study
Tomoya Fukui et al.
CLINICAL LUNG CANCER (2019)
Predicting marker for early progression in unresectable melanoma treated with nivolumab
Tomohiro Kondo et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2019)
Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors
Alberto Pavana et al.
ONCOLOGIST (2019)
Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: An updated meta-analysis of 17079 individuals
Wanying Guo et al.
CANCER MEDICINE (2019)
Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in patients with systemic lupus erythematosus and their correlation with activity: A meta-analysis
Lisha Ma et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2019)
Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab
Yeonghee Eun et al.
SCIENTIFIC REPORTS (2019)
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Satya Das et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
The Platelet-to-Lymphocyte Ratio as an Inflammatory Marker in Rheumatic Diseases
Armen Yuri Gasparyan et al.
ANNALS OF LABORATORY MEDICINE (2019)
Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies
Yoshiyuki Nakamura et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2019)
Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab
Rocco Giannicola et al.
MOLECULAR AND CLINICAL ONCOLOGY (2019)
Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab
Aya Nakaya et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2018)
Relationship between neutrophil lymphocyte ratio (NLR) and MDSC concentration in localized and metastatic castration resistant prostate cancer (mCRPC) patients.
Arnab Basu et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Myeloid-derived suppressor cells coming of age
Filippo Veglia et al.
NATURE IMMUNOLOGY (2018)
Association of Neutrophil-to-Lymphocyte Ratio With Mortality and Cardiovascular Disease in the Jackson Heart Study and Modification by the Duffy Antigen Variant
Stephanie Kim et al.
JAMA CARDIOLOGY (2018)
Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non-Small-cell Lung Cancer
Dwight H. Owen et al.
CLINICAL LUNG CANCER (2018)
Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials
Muhammad Khan et al.
MEDICINE (2018)
Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody
Koung Jin Suh et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab
Stefan Diem et al.
LUNG CANCER (2017)
The elevated NLR, PLR and PLT may predict the prognosis of patients with colorectal cancer: a systematic review and meta-analysis
Jie Zhang et al.
ONCOTARGET (2017)
Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer
Maria E. Suarez-Almazor et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Causes of variation in the neutrophil-lymphocyte and platelet-lymphocyte ratios: a twin-family study
Bochao D. Lin et al.
BIOMARKERS IN MEDICINE (2016)
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials
Holbrook E. Kohrt et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study
Viktor H. Koelzer et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients
Thomas Condamine et al.
SCIENCE IMMUNOLOGY (2016)
The prognostic landscape of genes and infiltrating immune cells across human cancers
Andrew J. Gentles et al.
NATURE MEDICINE (2015)
Phenotypic Diversity and Plasticity in Circulating Neutrophil Subpopulations in Cancer
Jitka Y. Sagiv et al.
CELL REPORTS (2015)
Ipilimumab Treatment Results in an Early Decrease in the Frequency of Circulating Granulocytic Myeloid-Derived Suppressor Cells as well as Their Arginase1 Production
Yago Pico de Coana et al.
CANCER IMMUNOLOGY RESEARCH (2013)
The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis
M. J. M. Gooden et al.
BRITISH JOURNAL OF CANCER (2011)
The platelet-lymphocyte ratio improves the predictive value of serum CA19-9 levels in determining patient selection for staging laparoscopy in suspected periampullary cancer
Richard A. Smith et al.
SURGERY (2008)
Share Paper
